Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-06-17
DOI
10.3389/fonc.2022.911876
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
- (2021) Manali Tilak et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- M2 macrophage-derived exosomal microRNAs inhibit cell migration and invasion in gliomas through PI3K/AKT/mTOR signaling pathway
- (2021) Jie Yao et al. Journal of Translational Medicine
- Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
- (2021) Javier Munoz et al. Targeted Oncology
- Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
- (2021) Nian N. N. Maarof et al. Cancers
- Current treatment options for HER2-positive breast cancer patients with brain metastases
- (2021) Daniele Galanti et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- RAS-targeted therapies
- (2021) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Sex-Specific Differences in Glioblastoma
- (2021) Anna Carrano et al. Cells
- Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
- (2020) Fumi Higuchi et al. CLINICAL CANCER RESEARCH
- KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway
- (2020) Yang Gao et al. JOURNAL OF NEURO-ONCOLOGY
- c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein
- (2020) Severa Bunda et al. MOLECULAR CANCER RESEARCH
- Tackling the Many Facets of Glioblastoma Heterogeneity
- (2020) Itay Tirosh et al. Cell Stem Cell
- Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
- (2020) Michaël H. Meel et al. CLINICAL CANCER RESEARCH
- CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells
- (2020) Yingxiao Cao et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Small molecules, big impact: 20 years of targeted therapy in oncology
- (2020) Philippe L Bedard et al. LANCET
- Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma
- (2020) Wen-Bin Yang et al. NEURO-ONCOLOGY
- Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
- (2020) Catherine Hanna et al. NEURO-ONCOLOGY
- Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
- (2020) Thomas J. Kaley et al. Annals of Clinical and Translational Neurology
- Selective inhibition of CDK4/6: a safe and effective strategy for developing anticancer drugs
- (2020) Kai Yuan et al. Acta Pharmaceutica Sinica B
- Management of glioblastoma: State of the art and future directions
- (2020) Aaron C. Tan et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Sequential changes in histone modifications shape transcriptional responses underlying microglia polarization by glioma
- (2020) Marta Maleszewska et al. GLIA
- HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models
- (2020) Trang Thi Thu Nguyen et al. JOURNAL OF CLINICAL INVESTIGATION
- PET, image-guided HDAC inhibition of pediatric diffuse midline glioma improves survival in murine models
- (2020) Umberto Tosi et al. Science Advances
- Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
- (2020) Mark Rosenthal et al. ESMO Open
- Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma
- (2020) Zachary Miklja et al. JOURNAL OF CLINICAL INVESTIGATION
- A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)
- (2020) Mariko DeWire et al. JOURNAL OF NEURO-ONCOLOGY
- A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
- (2020) Mark R Gilbert et al. NEURO-ONCOLOGY
- Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions
- (2020) Denis L. Jardim et al. ONCOLOGIST
- Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas
- (2020) Shaozhen Xie et al. Cell Reports
- The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance
- (2020) Filippo Torrisi et al. Cancers
- Upfront treatment with mTOR inhibitor everolimus in pediatric low‐grade gliomas: A single‐center experience
- (2020) Antonella Cacchione et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting phosphatidylinositol 3‐kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors
- (2020) Jingyu Zhu et al. MEDICINAL RESEARCH REVIEWS
- How selective are clinical CDK4/6 inhibitors?
- (2020) Denisa Hendrychová et al. MEDICINAL RESEARCH REVIEWS
- Molecular targets of tyrosine kinase inhibitors in thyroid cancer
- (2020) Poupak Fallahi et al. SEMINARS IN CANCER BIOLOGY
- Inhibition of TFEB oligomerization by co-treatment of melatonin with vorinostat promotes the therapeutic sensitivity in glioblastoma and glioma stem cells
- (2019) Gi-Jun Sung et al. JOURNAL OF PINEAL RESEARCH
- MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling
- (2019) Wei Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults
- (2019) Marte Karen Brattås et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma
- (2019) Jingwen Jiang et al. Autophagy
- Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas
- (2019) Rosângela Mayer Gonçalves et al. BIOCHEMICAL PHARMACOLOGY
- Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells
- (2019) Olivia Morris-Hanon et al. MOLECULAR NEUROBIOLOGY
- A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma
- (2019) Ekaterina Pak et al. NEURO-ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872
- (2019) Evanthia Galanis et al. CANCER
- Src and Fyn define a new signaling cascade activated by canonical and non-canonical Wnt ligands and required for gene transcription and cell invasion
- (2019) Aida Villarroel et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort
- (2019) An-Chi Tien et al. CLINICAL CANCER RESEARCH
- IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells
- (2019) Geon-Hee Kim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line
- (2019) Francesco P Cammarata et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ADAMDEC1 maintains a growth factor signaling loop in cancer stem cells
- (2019) Ana Jimenez-Pascual et al. Cancer Discovery
- Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
- (2019) Eudocia Q. Lee et al. Cancer Medicine
- Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG
- (2019) Jamie N. Anastas et al. CANCER CELL
- Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
- (2019) John D. Hainsworth et al. JOURNAL OF NEURO-ONCOLOGY
- A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
- (2019) Martin van den Bent et al. JOURNAL OF NEURO-ONCOLOGY
- Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models
- (2019) Caroline Von Achenbach et al. JOURNAL OF NEUROCHEMISTRY
- Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
- (2018) David Schiff et al. CANCER
- Combined c-Met/Trk inhibition overcomes resistance to CDK4/6 inhibitors in Glioblastoma
- (2018) Inan Olmez et al. CANCER RESEARCH
- Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas
- (2018) Sharmistha Pal et al. CANCER RESEARCH
- Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression
- (2018) Yu-Ting Wang et al. CANCER SCIENCE
- Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma
- (2018) Yiru Zhang et al. CLINICAL CANCER RESEARCH
- Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells
- (2018) Songlin Liu et al. INVESTIGATIONAL NEW DRUGS
- The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
- (2018) Claudio Festuccia et al. Journal of Hematology & Oncology
- Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF -Mutated High-Grade Glioma
- (2018) Tanner M. Johanns et al. Journal of the National Comprehensive Cancer Network
- Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products
- (2018) Kodappully S. Siveen et al. Molecular Cancer
- Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent
- (2018) Steven T. Sizemore et al. MOLECULAR CANCER RESEARCH
- mTOR inhibition in glioblastoma: requiem for a dream?
- (2018) Sam Babak et al. NEURO-ONCOLOGY
- Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2018) Gerald Edelman et al. ONCOLOGIST
- Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3
- (2018) Zhibo Dai et al. ONCOLOGY REPORTS
- Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma
- (2018) Alberto Broniscer et al. PEDIATRIC BLOOD & CANCER
- MerTK mediates STAT3–KRAS/SRC-signaling axis for glioma stem cell maintenance
- (2018) Hyojin Eom et al. Artificial Cells Nanomedicine and Biotechnology
- SIRT2‐mediated inactivation of p73 is required for glioblastoma tumorigenicity
- (2018) Kosuke Funato et al. EMBO REPORTS
- Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer.
- (2018) Neil Portman et al. ENDOCRINE-RELATED CANCER
- mTORC1 inhibition in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin
- (2018) Brad Poore et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015
- (2018) Quinn T Ostrom et al. NEURO-ONCOLOGY
- MiRNA-451 Inhibits Glioma Cell Proliferation and Invasion Through the mTOR/HIF-1α/VEGF Signaling Pathway by Targeting CAB39
- (2018) Yang Nan et al. Human Gene Therapy Clinical Development
- Targeting Upstream Kinases of STAT3 in Human Medulloblastoma cells
- (2018) Jia Wei et al. CURRENT CANCER DRUG TARGETS
- Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma
- (2018) Francesco Marampon et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Long noncoding RNA MEG3 inhibits proliferation and migration but induces autophagy by regulation of Sirt7 and PI3K/AKT/mTOR pathway in glioma cells
- (2018) Dong-Hui Xu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Drug development for glioma: are we repeating the same mistakes?
- (2018) Roger Stupp LANCET ONCOLOGY
- Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2018) Giuseppe Lombardi et al. LANCET ONCOLOGY
- Baicalin suppresses proliferation, migration, and invasion in human glioblastoma cells via Ca2+-dependent pathway
- (2018) Yihao Zhu et al. Drug Design Development and Therapy
- Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling
- (2017) Tian Lan et al. EXPERIMENTAL CELL RESEARCH
- Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme
- (2017) Khaled Greish et al. JOURNAL OF DRUG TARGETING
- Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
- (2017) Katherine B. Peters et al. JOURNAL OF NEURO-ONCOLOGY
- Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas
- (2017) Mei Liu et al. LABORATORY INVESTIGATION
- Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
- (2017) Hua-fu Zhao et al. Molecular Cancer
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
- (2017) Patrick Y Wen et al. NEURO-ONCOLOGY
- A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
- (2017) Prakash Chinnaiyan et al. NEURO-ONCOLOGY
- Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma
- (2017) Patrick Flannery et al. ONCOLOGY REPORTS
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- IDH -Mutant Tumors Vulnerable to PARP Inhibition
- (2017) Cancer Discovery
- Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness
- (2017) Jordi Rodon et al. Cancer Discovery
- High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response
- (2017) Olatz Arrizabalaga et al. Oncogenesis
- Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting
- (2017) Gretchen L. Gierach et al. JAMA Oncology
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways
- (2016) YiHan Wu et al. BIOMEDICINE & PHARMACOTHERAPY
- HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma
- (2016) Yanxin Pei et al. CANCER CELL
- Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity
- (2016) Zhiqiang Zhang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma
- (2016) Roman Reinartz et al. CLINICAL CANCER RESEARCH
- Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
- (2016) Andrew C. Wood et al. CLINICAL CANCER RESEARCH
- Epigenetics in Brain Tumors: HDACs Take Center Stage
- (2016) Ilker Y. Eyüpoglu et al. Current Neuropharmacology
- Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma
- (2016) Shinichi Watanabe et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Role of mTOR in glioblastoma
- (2016) Zekeriya Duzgun et al. GENE
- Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models
- (2016) NICOLE M. JONES et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report
- (2016) Magdalena Kusaczuk et al. INVESTIGATIONAL NEW DRUGS
- Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells
- (2016) Ming Luo et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
- (2016) Caroline Happold et al. JOURNAL OF CLINICAL ONCOLOGY
- Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide
- (2016) Navid Redjal et al. JOURNAL OF NEURO-ONCOLOGY
- Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
- (2016) I. A. Netland et al. JOURNAL OF NEURO-ONCOLOGY
- Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island
- (2016) Sebastian I. Arriola Apelo et al. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
- Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling
- (2016) Kristin B. Runkle et al. MOLECULAR CELL
- Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma
- (2016) Rikke D. Rasmussen et al. Molecular Oncology
- Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth
- (2016) Rintaro Hashizume et al. NEURO-ONCOLOGY
- EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation
- (2016) Eskil Eskilsson et al. NEURO-ONCOLOGY
- Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines
- (2016) Zong-yang Li et al. NEUROCHEMICAL RESEARCH
- A comprehensive profile of recurrent glioblastoma
- (2016) B Campos et al. ONCOGENE
- Honokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathway
- (2016) Chien-Ju Lin et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
- (2016) Mélissa Carbonneau et al. Nature Communications
- BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
- (2016) Maria-Carmela Speranza et al. Scientific Reports
- Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system
- (2015) Sebastian I. Arriola Apelo et al. AGING CELL
- A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors
- (2015) H. Henary et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells
- (2015) Lotte M.E. Berghauser Pont et al. CANCER LETTERS
- NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
- (2015) Zhiyun Yu et al. CANCER LETTERS
- A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
- (2015) E. Q. Lee et al. CLINICAL CANCER RESEARCH
- NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5
- (2015) KIMBERLY A. FOSTER et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study
- (2015) H. Ian Robins et al. JOURNAL OF NEURO-ONCOLOGY
- Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition
- (2015) M. Mehta et al. MOLECULAR CANCER THERAPEUTICS
- Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
- (2015) Catherine S Grasso et al. NATURE MEDICINE
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
- (2015) E. Q. Lee et al. NEURO-ONCOLOGY
- Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma
- (2015) Melissa M. Singh et al. NEURO-ONCOLOGY
- Dasatinib in recurrent glioblastoma: failure as a teacher
- (2015) David Schiff et al. NEURO-ONCOLOGY
- Prognostic relevance of epilepsy at presentation in glioblastoma patients
- (2015) Sharon Berendsen et al. NEURO-ONCOLOGY
- PKCδ maintains phenotypes of tumor initiating cells through cytokine-mediated autocrine loop with positive feedback
- (2015) R-K Kim et al. ONCOGENE
- Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
- (2015) Katrin Liffers et al. Targeted Oncology
- FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells
- (2015) Li Zhang et al. TOXICOLOGY LETTERS
- Role of ErbB Receptors in Cancer Cell Migration and Invasion
- (2015) Aline Appert-Collin et al. Frontiers in Pharmacology
- Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
- (2015) Jonas Ecker et al. Acta Neuropathologica Communications
- Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors
- (2014) Megumi Inada-Inoue et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PARP inhibitors and IR join forces to strike glioblastoma-initiating cells
- (2014) N Lugli et al. CELL DEATH AND DIFFERENTIATION
- Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase i inhibitor or radiation
- (2014) Francesco Sabbatino et al. CYTOMETRY PART A
- The role of Src family kinases in growth and migration of glioma stem cells
- (2014) XIAOSI HAN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma
- (2014) Phyllis R. Wachsberger et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Sorafenib/Regorafenib and Lapatinib Interact to kill CNS Tumor Cells
- (2014) Hossein A. Hamed et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma
- (2014) Jennie W. Taylor et al. JOURNAL OF NEURO-ONCOLOGY
- Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma
- (2014) Nathalène Truffaux et al. NEURO-ONCOLOGY
- Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways
- (2014) Eva Bernhart et al. NEURO-ONCOLOGY
- A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma
- (2014) J. L. Clarke et al. NEURO-ONCOLOGY
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
- (2014) P. Y. Wen et al. NEURO-ONCOLOGY
- Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines
- (2014) Joshua C. Anderson et al. RADIOTHERAPY AND ONCOLOGY
- Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNF in glioblastoma
- (2014) Y. Kusne et al. Science Signaling
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells
- (2013) M Venere et al. CELL DEATH AND DIFFERENTIATION
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
- (2013) E. Galanis et al. CLINICAL CANCER RESEARCH
- A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
- (2013) D. A. Reardon et al. CLINICAL CANCER RESEARCH
- Pazopanib, a new therapy for metastatic soft tissue sarcoma
- (2013) Jaap Verweij et al. EXPERT OPINION ON PHARMACOTHERAPY
- Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival
- (2013) Christopher A. Barker et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
- (2013) Chudi O. Ndubaku et al. JOURNAL OF MEDICINAL CHEMISTRY
- A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas
- (2013) Vasilios Karavasilis et al. JOURNAL OF NEUROLOGY
- NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme
- (2013) David M. Peereboom et al. NEURO-ONCOLOGY
- Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme
- (2013) M. Kerkhof et al. NEURO-ONCOLOGY
- Valproic acid pathway
- (2013) Yogita Ghodke-Puranik et al. Pharmacogenetics and Genomics
- Comparison of HDAC inhibitors in clinical development
- (2013) Thomas Aagaard Rasmussen et al. Human Vaccines & Immunotherapeutics
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
- (2012) Jian Chen et al. CELL
- Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts
- (2012) G. J. Kitange et al. CLINICAL CANCER RESEARCH
- Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
- (2012) C. Leonetti et al. CURRENT CANCER DRUG TARGETS
- PARP-1 protein expression in glioblastoma multiforme
- (2012) A. Galia et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- Safety and tolerability of pazopanib in the treatment of renal cell carcinoma
- (2012) Andrea Zivi et al. Expert Opinion On Drug Safety
- Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
- (2012) Katharina Seystahl et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
- (2012) Maja J. A. de Jonge et al. INVESTIGATIONAL NEW DRUGS
- Continuous daily sunitinib for recurrent glioblastoma
- (2012) Teri Nguyen Kreisl et al. JOURNAL OF NEURO-ONCOLOGY
- Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
- (2012) E. Q. Lee et al. NEURO-ONCOLOGY
- EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma
- (2012) E. Franceschi et al. NEURO-ONCOLOGY
- p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
- (2012) L. Cen et al. NEURO-ONCOLOGY
- PARP-1 Inhibitors DPQ and PJ-34 Negatively Modulate Proinflammatory Commitment of Human Glioblastoma Cells
- (2012) Marina Scalia et al. NEUROCHEMICAL RESEARCH
- Early prediction of response to Vorinostat in an orthotopic rat glioma model
- (2012) Li Wei et al. NMR IN BIOMEDICINE
- Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
- (2011) Genevieve Schindler et al. ACTA NEUROPATHOLOGICA
- eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206
- (2011) Y. Cheng et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
- (2011) D. Koul et al. CLINICAL CANCER RESEARCH
- Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic
- (2011) Jacob E. Shabason et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis
- (2011) Y. Cheng et al. MOLECULAR CANCER THERAPEUTICS
- A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
- (2011) J. J. Raizer et al. NEURO-ONCOLOGY
- Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
- (2011) P. C. De Witt Hamer NEURO-ONCOLOGY
- Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
- (2011) B. B. Friday et al. NEURO-ONCOLOGY
- Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma
- (2011) Prakash Chinnaiyan et al. NEURO-ONCOLOGY
- Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target
- (2011) S. J. Smith et al. NEURO-ONCOLOGY
- Pathway inhibition: emerging molecular targets for treating glioblastoma
- (2011) W. Wick et al. NEURO-ONCOLOGY
- A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
- (2011) Fabio M. Iwamoto et al. NEURO-ONCOLOGY
- Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
- (2011) M. Weller et al. NEUROLOGY
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
- (2011) Matthew T. Burger et al. ACS Medicinal Chemistry Letters
- Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
- (2010) R A Daniel et al. BRITISH JOURNAL OF CANCER
- Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme
- (2010) John D. Hainsworth et al. CANCER
- Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies
- (2010) Manmeet S. Ahluwalia et al. CANCER LETTERS
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) B. McEllin et al. CANCER RESEARCH
- Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma
- (2010) Jan Drappatz et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
- (2010) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
- (2010) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
- (2010) F. M. Iwamoto et al. NEURO-ONCOLOGY
- Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
- (2010) Margaret J. Dougherty et al. NEURO-ONCOLOGY
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
- (2010) W. R. Wiedemeyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry
- (2010) Maxim Isabelle et al. Proteome Science
- Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
- (2009) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
- (2009) David A. Reardon et al. CANCER
- A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
- (2009) Brian Thiessen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- (2009) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
- (2009) Gregor Dresemann et al. JOURNAL OF NEURO-ONCOLOGY
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
- (2009) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- The Protein Phosphatase Activity of PTEN Regulates Src Family Kinases and Controls Glioma Migration
- (2008) N. Dey et al. CANCER RESEARCH
- Pten Haploinsufficiency Accelerates Formation of High-Grade Astrocytomas
- (2008) C.-H. Kwon et al. CANCER RESEARCH
- Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential
- (2008) Fiona A. Dungey et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients
- (2008) O. Johnston et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma
- (2008) David A. Reardon et al. NEURO-ONCOLOGY
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
- A Phase I Dose-Escalation Study of Fractionated Stereotactic Radiosurgery in Combination With Gefitinib in Patients With Recurrent Malignant Gliomas
- (2007) Amanda L. Schwer et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started